Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal systems for overactive bladder: principles and practice.

David R Staskin

    Reviews in Urology
    |September 21, 2006
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Feasibility of a Fully Implanted, Nickel Sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence.

    The Journal of urology·2019
    Same author

    Combination Therapy for Overactive Bladder: Who Approves?

    European urology·2018
    Same author

    Development of oxybutynin chloride topical gel for overactive bladder.

    Open access journal of urology·2013
    Same author

    Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.

    Clinical drug investigation·2012
    Same author

    Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care.

    Current urology reports·2012
    Same author

    Conflict of interest--who benefits?

    Neurourology and urodynamics·2012
    Same journal

    Erratum: Author's Name Correction for "From Radical to Partial Nephrectomy in the Setting of Solitary Functioning Kidney: Neoadjuvant Treatment of Renal Cell Carcinoma".

    Reviews in urology·2021
    Same journal

    Update in Female Hormonal Therapy: What the Urologist Should Know: NYU Case of the Month, December 2020.

    Reviews in urology·2021
    Same journal

    Genetic Mutations Associated With Prostate Cancer and Normal Serum PSA and DRE-Implications for Prostate Cancer Screening and Management: NYU Case of the Month, November 2020.

    Reviews in urology·2021
    Same journal

    Surgical Management of the "Large" Prostate: The Robotic Simple Prostatectomy: NYU Case of the Month, October 2020.

    Reviews in urology·2021
    Same journal

    Cryptozoospermia Associated With Genital Tucking Behavior in a Transwoman.

    Reviews in urology·2021
    Same journal

    Washington Roundup.

    Reviews in urology·2021
    See all related articles

    A new oxybutynin transdermal system for overactive bladder offers better tolerability and efficacy. This patch improves drug delivery by bypassing metabolism and enhancing skin absorption, benefiting patients needing convenient medication options.

    Area of Science:

    • Pharmacology
    • Dermatology
    • Drug Delivery Systems

    Background:

    • Overactive bladder (OAB) treatments often face challenges with efficacy and tolerability.
    • Oral medications for OAB are subject to gastrointestinal and hepatic metabolism, potentially affecting therapeutic outcomes.
    • Transdermal drug delivery offers an alternative route to manage OAB symptoms.

    Purpose of the Study:

    • To evaluate a novel transdermal system for oxybutynin delivery in treating overactive bladder.
    • To assess the efficacy-to-tolerability ratio of the transdermal system compared to traditional methods.
    • To determine if the transdermal system can achieve clinical efficacy with a lower drug burden and improved patient compliance.

    Main Methods:

    • Development of a novel transdermal patch containing oxybutynin and a skin permeation enhancer.

    Related Experiment Videos

  • Clinical trials to evaluate the patch's performance, including drug absorption, skin integrity, and cosmetic acceptability.
  • Assessment of serum drug levels and comparison with oral administration routes.

    • Main Results:

    • The novel transdermal system demonstrated improved efficacy-to-tolerability ratio.
    • Consistent drug absorption and predictable release of oxybutynin and permeation enhancer were achieved.
    • The system maintained skin integrity and was cosmetically acceptable to patients.

    Conclusions:

    • Transdermal oxybutynin delivery provides a viable alternative for overactive bladder treatment.
    • This system offers advantages such as avoiding first-pass metabolism and improving patient compliance.
    • The patch system successfully met key performance criteria for efficient and acceptable drug delivery.